Pfizer Inc reported results for the 2026 quarter with revenue of $15.03B, a year-over-year rise of 2.6%, while net income swung to a loss of ($248M) and diluted EPS was ($0.04), compared with $2.91B and $0.51, respectively, in the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$15.03B$14.65B2.6% | Net income²($248M)$2.91B(108.5%) | Diluted EPS³($0.04)$0.51(107.8%) |
¹ Reported as “Total revenues”. ² Reported as “Net income/(loss) attributable to Pfizer Inc. common shareholders”. ³ Reported as “Earnings/(loss) per common share––diluted”.
Business Highlights
- Revenue growth was driven by strong performance from Eliquis, Padcev, Vyndaqel and Lorbrena; COVID-19 product volumes and government purchases continued to decline materially.
- U.S. net price dynamics and lower rebates supported Eliquis results.
- New launches and uptake bolstered brands including Padcev, Lorbrena, Nurtec ODT/Vydura and Abrysvo; approvals and filings expanded indications and markets.
- Management announced cost-savings programs: a $6.7B Realigning plan and $3.0B Manufacturing Optimization initiative through 2029, targeting synergies with Metsera.
- R&D spending increased in oncology and obesity with multiple approvals and late-stage filings in 2026; certain programs were withdrawn or halted, including Oxbryta.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.